Recent

% | $
Quotes you view appear here for quick access.

OCATA THERAPEUTICS, INC. Message Board

beareclawe 554 posts  |  Last Activity: 5 hours ago Member since: Jan 10, 2011
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    A Lot of Uncertainty But One Thing Is Certain

    by hschlauch Feb 11, 2015 7:33 PM
    beareclawe beareclawe 5 hours ago Flag

    bump for:

    the rabidly optimistic, unconscionable, and conjecture-based
    hschlauch and the short and distort group
    the anxious and desperate
    the spin/pump chimps

    : ) Giddy up !

  • Reply to

    Will this be the payoff for 8

    by booskiadam Feb 25, 2015 7:08 AM
    beareclawe beareclawe 8 hours ago Flag

    Re: Do you know why you are here? Do you own OCAT stock?

    It's not important for you to know. It's only important for me to know.

    : ) That's bearecraft.

  • Reply to

    Will this be the payoff for 8

    by booskiadam Feb 25, 2015 7:08 AM
    beareclawe beareclawe 9 hours ago Flag

    Re: What advantage is there ....

    booskiadam • 27 minutes ago
    As long as I have been here I havent has such an amount of good news yet felt so melancholy about our future.... Seems all the milestones mean nothing without the science and _____________ nothing from OCAT about that!

    : )

  • Reply to

    A Lot of Uncertainty But One Thing Is Certain

    by hschlauch Feb 11, 2015 7:33 PM
    beareclawe beareclawe 9 hours ago Flag

    Re: On a long-term basis, we have no expectation of generating any meaningful revenues from our product candidates for a substantial period of time and must rely on raising funds in capital transactions to finance our research and development programs.

    Food for thought....

    Citation:

    "As part of that deal, Novartis has already paid Ophthotech $200 million, and Ophthotech could receive up to another $800 million in milestones if Fovista pans out."

    3 Little-Known Biotechs Working On Potential Blockbusters
    The Motley Fool
    By Todd Campbell
    March 28, 2015
    (excerpt)
    No 1: Ophthotech Corp. (NASDAQ: OPHT )
    First up is Ophthotech, a clinical-stage biotech that is developing a drug that can be used alongside Novartis (NYSE: NVS ) and Regeneron's (NASDAQ: REGN ) blockbuster wet-age related macular degeneration, or wet-AMD, drugs Lucentis and Eylea.

    Both Novartis and Regeneron are reaping multibillions of dollars in sales for their wet-AMD drugs, and given that aging baby boomers are likely to increase the prevalence of this age related disease in the coming decade, new therapies like Ophthotech's Fovista could similarly put up blockbuster sales numbers one day.

    Fovista is currently in phase 3 trials, so the drug isn't up for consideration by the FDA yet. But results from previous trials have been compelling. In one mid-stage study, using Fovista alongside Novartis' Lucentis improved vision by 10.6 letters on a standard eye chart versus 6.5 letters for patients receiving Lucentis alone. Those results were good enough for Novartis to agree to license rights to Fovista overseas.

    As part of that deal, Novartis has already paid Ophthotech $200 million, and Ophthotech could receive up to another $800 million in milestones if Fovista pans out. The fact that Ophthotech has a been-there-done-that partner with deep pockets, and in a proven indication, is particularly intriguing when we consider that Ophthotech's market cap is less than $2 billion.

    : )

  • Reply to

    A Lot of Uncertainty But One Thing Is Certain

    by hschlauch Feb 11, 2015 7:33 PM
    beareclawe beareclawe 10 hours ago Flag

    Re: The question of funding will imo be addressed by the company once they are on Nasdaq.

    03/16/15 10-K

    (excerpt)

    We plan to fund our operations for the foreseeable future from the following sources: As of December 31, 2014, we have approximately $4,424,374 in cash. As of December 31, 2014, $18,619,451 is available to us through the Lincoln Park financing arrangement. On various dates from January 1, 2015 through March 16, 2015, Lincoln Park purchased 932,182 shares of common stock for cash proceeds to the Company of $5,872,996. As of March 16, 2015, the Company has $12,746,455 available to us through the Lincoln Park financing arrangement.

    On a long-term basis, we have no expectation of generating any meaningful revenues from our product candidates for a substantial period of time and must rely on raising funds in capital transactions to finance our research and development programs. Our future cash requirements will depend on many factors, including the pace and scope of our research and development programs, the costs involved in filing, prosecuting and enforcing patents, and other costs associated with commercializing our potential products.



    We believe that our current cash balance, and the $18,619,451 available to us under the Lincoln Park financing arrangement, will be sufficient to fund our operations into early 2016. This belief is based on the assumption that our stock price does not realize any significant or prolonged decreases. Our ability to fund our operations through the Lincoln Park arrangement is highly dependent on our stock price. A significant decline in our share price could force us to curtail our operations in part, or entirely. We are continually in discussions with potential investors and collaborators to explore alternative sources of funding which may or may not result in immediate and substantial dilution to our stockholders, so that we may either extend our current cash runway beyond early 2016 or accelerate the rate of investment in our many clinical and pre-clinical programs.



    We cannot assure you that public or private financing or grants will be available on acceptable terms, if at all. Several factors will affect our ability to raise additional funding, including, but not limited to, the volatility of our common stock and the broader public equity market. If we are unable to raise additional funds, we will be forced to either scale back our business efforts or curtail our business activities entirely. As of December 31, 2014, the Company has an accumulated deficit of $349.1 million, recurring losses from operations, and negative working capital which raise substantial doubt about the ability of the Company to continue as a going concern. Furthermore, an emphasis of matter paragraph related to an uncertainty as to the Company’s ability to continue as a going concern has been included in the auditor’s opinion.

    : )

  • Reply to

    A Lot of Uncertainty But One Thing Is Certain

    by hschlauch Feb 11, 2015 7:33 PM
    beareclawe beareclawe 11 hours ago Flag

    Re: The question of funding will imo be addressed by the company once they are on Nasdaq.

    Conference Call, March 12, 2015

    (excerpt)

    Ted Myles: Thanks Paul. A key objective on the corporate side is to properly capitalize the company. This includes attracting institutional capital from investors who can partner with us over the long term and who can invest the level of capital required to fully fund our clinical trials. A critical step in this process was our recent accomplishment of uplisting our stock to NASDAQ. As many of you know, we began trading on the NASDAQ Global Market on February 26th under the ticker symbol OCAT. Uplisting the company's stock to NASDAQ has been an objective of the company for a long time. Aside from all of the obvious benefits of being a NASDAQ-listed company, we also believe that this listing allows us to demonstrate that we have resolved the legacy issues inherited from prior management. This allows us to move forward with a fresh start for the company.

    Moving to financial results for 2014, I want to highlight two line items.

    First, R&D expenses, excluding non-cash stock compensation, were approximately $9.6 million dollars for the full year. While this was a decrease compared to 2013, we expect R&D to increase year over year in 2015 as we initiate the next phase of our clinical trials.

    G&A expenses, excluding non-cash stock compensation, decreased to approximately $9.2 million dollars in 2014. We expect this trend to continue as we believe we have resolved our legacy legal matters and therefore don't expect to incur significant legal costs related to those matters.

    As of December 31, 2014, we had approximately $4.4 million dollars of cash and cash equivalence on hand and approximately $18.6 million dollars available to us under our arrangement with Lincoln Park Capital. As previously disclosed, we initiated the process of marketing the company to institutional investors in the 4th quarter of last year. We were pleased with the reception we received from several high-quality investors, and now that we have achieved the NASDAQ listing and we're nearing the initiation of our Phase II clinical trials, we look forward to reengaging the market and ultimately attracting institutional capital into Ocata. We look forward to updating you further as we continue to make progress against our plan, and we appreciate your continued support. Now I'll turn the call back to Paul.

    : )

  • Reply to

    Thank GAWD for Lincoln

    by booskiadam Mar 3, 2015 6:36 PM
    beareclawe beareclawe 11 hours ago Flag

    Re: 6 more weeks

    Yea, you've waited eight years....... What's '6 more weeks.'

    booskiadam • Feb 25, 2015 7:08 AM
    Will this be the payoff for 8
    years of patience and accumulation?

    : )

  • Reply to

    Thank GAWD for Lincoln

    by booskiadam Mar 3, 2015 6:36 PM
    beareclawe beareclawe 12 hours ago Flag

    Re: Lincoln Park Financial set up a $55 million line of vulture financing for Galena Biopharma last week, the scandal-ridden bio-tech company ............ Lincoln Park's involvement here is interesting in that these are the guys willing to throw a cash lifeline to companies unable to raise money via a traditional stock offering.

    'Galena, Shunned by Wall Street, Forced to Seek Pricey Vulture Financing' ............ Ocata Therapeutics, too ?

    Press Releases
    February 26, 2015
    Ocata Therapeutics Approved for Listing on NASDAQ

    February 11, 2015
    Ocata Therapeutics Withdraws Offering of Common Stock

    December 2, 2014
    Ocata Therapeutics Announces Proposed Underwritten Offering of Common Stock

    August 27, 2014
    Advanced Cell Technology Announces 1:100 Reverse Stock Split

    07/03/14 S-3
    (commitment fee)
    As of June 30, 2014, we have issued 10,600,707 shares of our common stock to Lincoln Park pursuant to the terms of the Purchase Agreement as consideration for its commitment to purchase additional shares of our common stock under the Purchase Agreement.

    July 3, 2014
    Advanced Cell Technology Secures $30 Million Equity Facility from Lincoln Park Capital

    : ) Pixels are mightier than the sword.

  • Reply to

    Thank GAWD for Lincoln

    by booskiadam Mar 3, 2015 6:36 PM
    beareclawe beareclawe 14 hours ago Flag

    Re: Loan sharks are propping us up!

    teratomass • Nov 26, 2014 9:26 AM
    Vulture Financing
    Ocata Therapeutics : Down 13% since Lincoln Park started buying the company's stock in July. And Soligenix shares have lost 17% of their value since the November 2013 Lincoln Park financing. Lincoln Park Financial set up a $55 million line of vulture financing for Galena Biopharma last week, the scandal-ridden bio-tech company still under active SEC investigation for paying outside firms to promote its stock while insiders made millions of dollars selling company shares. Lincoln Park's involvement here is interesting in that these are the guys willing to throw a cash lifeline to companies unable to raise money via a traditional stock offering. Galena, according to a source familiar with the company's funding shortfall, was unable to muster sufficient interest from institutional investors. So, Galena has apparently turned to Lincoln Park, which has a reputation for financing troubled biotech companies -- but at great cost. Google any sentence to read full story

    : )

  • beareclawe beareclawe Mar 30, 2015 3:45 PM Flag

    Re: $30.00 per share covers just the platelet program.

    "While the early data that we have generated are encouraging, we believe that our limited resources are best allocated to our other programs, at this time. In the future we may look to partner this program, pursue government funding or permanently cancel the program."

    Citation:

    03/16/15 10-K
    (excerpt)

    Platelets

    Platelets are key elements in maintaining blood vessel integrity, or hemostasis, and are therefore central to wound healing and tissue regeneration after injury or surgery. Platelets are a mainstay in treating trauma, and are increasingly being used to promote healing from a wide range of surgeries. When platelet levels decrease and result in thrombocytopenia, such as when bone marrow is destroyed or suppressed, the decrease in platelet function is often a leading cause of morbidity.

    Platelets are the most difficult blood product to maintain. They cannot be frozen or refrigerated. Instead, they must be stored at room temperature which limits the shelf life of platelets to five to seven days both because of loss of activity and risk of bacterial contamination during storage. Accordingly, it is our belief that the practical use of platelets is limited by availability. Our estimates are that, but for limitations on donated platelet supplies, there would be a demand for a substantial number of additional units of platelets each year beyond the current platelet usage, particularly for expanded use in surgical settings such as joint replacement or to prevent scarring.

    We have developed a manufacturing process for generating megakaryocytes, proplatelet forming cells and ultimately platelets using either hESCs or iPSCs as the starting materials. This process can be carried out under GMP conditions, and we are approaching the ability to produce clinical doses of platelets. We have also solved an important problem in this process, in that we have developed a feeder-free process for making platelets from start to finish. This means our process may be portable into a continuous flow bioreactor to permit large-scale manufacturing.

    Overall, we observe that the platelets made by our stem cell process have ultrastructural and morphological features that are indistinguishable from normal blood platelets. We believe our platelets function appropriately as well, both in vitro and in vivo. They respond to thrombin stimulation, form micro-aggregates, and facilitate clot formation and retraction. In animal models of injury, our stem cell derived platelets contribute to developing thrombi at sites of vascular injury.

    While the early data that we have generated are encouraging, we believe that our limited resources are best allocated to our other programs, at this time. In the future we may look to partner this program, pursue government funding or permanently cancel the program.

    : )

  • beareclawe beareclawe Mar 30, 2015 12:54 PM Flag

    bump for:

    the rabidly optimistic, unconscionable, and conjecture-based
    hschlauch and the short and distort group
    the anxious and desperate
    the spin/pump chimps

    : ) Giddy up !

  • beareclawe beareclawe Mar 30, 2015 12:42 PM Flag

    Re: Freddy promised that Lanza would bring forth fiches from the waters.

    "Freddy the demon is a liar."

    father_merrin • Mar 2, 2015 3:02 PM
    Freddy the demon is a liar.
    Especially important is the warning to avoid conversations with the demon. We may ask what is relevant but anything beyond that is dangerous. He is a liar. Freddy the demon is a liar. He will lie to confuse us. But he will also mix lies with the truth to attack us. The attack is psychological and powerful. So don't listen to him. Remember that - do not listen.

    : ) When freddy)0(phelps lies he speaks his native language.

  • beareclawe beareclawe Mar 30, 2015 12:34 PM Flag

    Re: Document Type and Number: United States Patent 8962321

    freddy)0(phelps,

    If you wanna be OCATs yahoo finance message board representative..... please ensure your messages are complete and accurate. THX

    : )

  • beareclawe beareclawe Mar 30, 2015 12:13 PM Flag

    Re: Document Type and Number: United States Patent 8962321

    Press Releases
    February 25, 2015
    Ocata Therapeutics Receives Two New Patents for Immune-modulatory Cell Technology
    Potential Treatment of Ophthalmic, Autoimmune and Inflammatory Diseases using Ocata’s Proprietary HMC™ Technology

    (excerpt)

    MARLBOROUGH, Mass.-- Ocata Therapeutics, Inc. (“Ocata” or “the Company”; OTCBB: OCAT), a leader in the field of Regenerative OphthalmologyTM, today announced that the United States Patent and Trademark Office (USPTO) issued two U.S. Patents, Nos. 8,962,321 and 8,961,956, directed to the Company’s Hemangio-derived Mesenchymal Cells (“HMCs”).

    : )

  • beareclawe beareclawe Mar 30, 2015 12:07 PM Flag

    Re: All Longs Need to Read ...

    "Our goal is to conduct a limited number of pre-clinical proof-of-concept studies, and based on those results, advance certain of these HMC discovery programs into IND-enabling pre-clinical studies and perhaps file IND applications, as circumstances dictate. In parallel, we are evaluating opportunities for strategic partnering relationships, out-licensing or other commercial transactions with outside parties, such as large pharmaceutical and biotech companies, with the objective of obtaining external funding for these programs so they may continue to be advanced with minimal costs to our company."

    03/16/15 10-K
    (excerpt)
    Hemangio-derived Mesenchymal Cells™

    Pluripotent stem-cell derived mesenchymal stem cells (MSCs) regulate immune and inflammatory responses, making them an attractive tool for the treatment of autoimmunity and inflammation. Their underlying molecular mechanisms of action together with their clinical benefit — for example, in autoimmunity — are, in our opinion, being revealed by an increasing number of clinical trials and pre-clinical studies of MSCs. The immunosuppressive/ immunomodulatory activity of these cells allows MSCs to be transplanted nearly universally, i.e., as an allogeneic cell therapy, without matching between donors and recipients. This versatility, along with the ability to manufacture and store these cells, presents a unique opportunity to produce an "off-the-shelf" cellular therapy ready for treatment of diseases in both acute and chronic settings.



    Current competitive MSC products for therapeutic applications are isolated from donor-dependent primary tissue sources such as umbilical cord, bone marrow, and adipose (fat) tissue. To achieve commercial scale quantities, MSCs isolated from these tissues need to be expanded in culture, yet the process of expansion compromises the therapeutic potency of these cells. Accordingly, the number of doses of MSCs that can be generated from each donor must be limited in order to preserve potency. Multiple donors must therefore be used to achieve large scale manufacturing required for an off-the-shelf therapy. The use of multiple donors introduces variability in the final MSC product and also drives up costs as pathogen screening must be performed for each new donor.



    We believe we have succeeded at creating a unique cellular product, which we refer to as Hemangio-derived Mesenchymal Cells™ (“HMC’s) with attributes similar to MSCs but that circumvent the issues encountered with donor-dependent sources, Our HMCs are produced from a single, pluripotent stem cell source, the renewable nature of which, permits us to manufacture large scale quantities of HMCs without the need for extensive in vitro culture, thus preserving their potency. The stem-cell-sourced manufacturing process may be scalable for global commercialization and therefore may prove to be less costly (particularly at commercial scale) than the primary tissue-sourced MSC products in development by other companies.



    Pre-clinical testing of our stem cell-derived HMCs has demonstrated their therapeutic efficacy in various autoimmune disease models. During the course of this testing, we noted another differentiating feature of our cells: the HMCs generated using our proprietary manufacturing approach appear to be more potent with respect to suppressing autoimmune disease than equivalent doses of bone marrow MSCs. This potency was dependent on the number of passages in culture, with the earlier passage HMCs retaining the greatest potency. This correlates with reports in the scientific literature which suggest that not only does the time in culture affect MSC potency but the age of the tissue source affects its potency as well. Evidence in the field suggests that MSCs from young tissue sources, such as embryonic, may be more potent than those from adult (e.g., bone marrow or adipose) tissue sources. Being derived from embryonic stem cells, the early-passage HMCs we are testing for potential therapeutic use are both youthful and replenishable, representing the earliest and most potent stage of biological development.



    Our goal is to conduct a limited number of pre-clinical proof-of-concept studies, and based on those results, advance certain of these HMC discovery programs into IND-enabling pre-clinical studies and perhaps file IND applications, as circumstances dictate. In parallel, we are evaluating opportunities for strategic partnering relationships, out-licensing or other commercial transactions with outside parties, such as large pharmaceutical and biotech companies, with the objective of obtaining external funding for these programs so they may continue to be advanced with minimal costs to our company.



    : )

  • beareclawe beareclawe Mar 30, 2015 7:10 AM Flag

    Re: Where is my commentary discussing this topic? And where is your commentary discussing anything of substance?

    Blame it on the short and distort crew.

    hschlauch • Feb 12, 2015 1:37 PM
    The short and distort crew have been trying to hide all useful information on this board for months on end.

    hschlauch • Feb 12, 2015 4:26 PM
    The short and distort group try to bury informational posts. They won't respond to educational discussions because it perpetuates good information.

    hschlauch • Feb 16, 2015 6:47 PM
    There is certainly an effort on this board, whether it is by a few or more than a few, who want to bury the discussions about the scientific publications, patents, market potential, valuations, number of outstanding shares, etc. They rarely contribute to those discussions because they make the company look good and they perpetuate good dialogue. They resort to personal attacks, misinformation and a distortion of the facts to scare away investors. I see this as a short and distort campaign similar to pumping and dumping, just the mirror opposite. Most of them spend every day on this board to ensure that it gets cluttered with nonsense. This has the effect of burying positive information about the company. Propaganda is the oldest trick in the book, but novices always fall for it.

    : ) This is beareclawe...... wishing YOU good mental health !

  • Reply to

    CC

    by blackmarango Mar 12, 2015 3:13 PM
    beareclawe beareclawe Mar 29, 2015 7:47 PM Flag

    bump for:

    rabidly optimistic, unconscionable, and conjecture-based
    hschlauch and the short and distort group
    anxious and desperate
    spin/pump chimps

    : ) Giddy up !

  • beareclawe beareclawe Mar 29, 2015 6:33 PM Flag

    Re: REGN

    Citation:

    Conference Call, March 12, 2015
    (excerpt)
    Paul Wotton: One product, for example Eyelea, marketed by Regeneron for wet AMD, exceeded $1.7 billion in sales in 2014 in only its third year on the market. This highlights the extent of the AMD disorder, which is rapidly becoming an epidemic in this and other developed countries.

    3 Little-Known Biotechs Working On Potential Blockbusters
    The Motley Fool
    By Todd Campbell
    March 28, 2015
    (excerpt)
    No 1: Ophthotech Corp. (NASDAQ: OPHT )
    First up is Ophthotech, a clinical-stage biotech that is developing a drug that can be used alongside Novartis (NYSE: NVS ) and Regeneron's (NASDAQ: REGN ) blockbuster wet-age related macular degeneration, or wet-AMD, drugs Lucentis and Eylea.

    Both Novartis and Regeneron are reaping multibillions of dollars in sales for their wet-AMD drugs, and given that aging baby boomers are likely to increase the prevalence of this age related disease in the coming decade, new therapies like Ophthotech's Fovista could similarly put up blockbuster sales numbers one day.

    Fovista is currently in phase 3 trials, so the drug isn't up for consideration by the FDA yet. But results from previous trials have been compelling. In one mid-stage study, using Fovista alongside Novartis' Lucentis improved vision by 10.6 letters on a standard eye chart versus 6.5 letters for patients receiving Lucentis alone. Those results were good enough for Novartis to agree to license rights to Fovista overseas.

    As part of that deal, Novartis has already paid Ophthotech $200 million, and Ophthotech could receive up to another $800 million in milestones if Fovista pans out. The fact that Ophthotech has a been-there-done-that partner with deep pockets, and in a proven indication, is particularly intriguing when we consider that Ophthotech's market cap is less than $2 billion.

    : )

  • Reply to

    CC

    by blackmarango Mar 12, 2015 3:13 PM
    beareclawe beareclawe Mar 29, 2015 2:35 PM Flag

    Re: One product, for example Eyelea, marketed by Regeneron for wet AMD, exceeded $1.7 billion in sales in 2014 in only its third year on the market. This highlights the extent of the AMD disorder, which is rapidly becoming an epidemic in this and other developed countries.

    3 Little-Known Biotechs Working On Potential Blockbusters
    The Motley Fool
    By Todd Campbell
    March 28, 2015
    (excerpt)
    No 1: Ophthotech Corp. (NASDAQ: OPHT )
    First up is Ophthotech, a clinical-stage biotech that is developing a drug that can be used alongside Novartis (NYSE: NVS ) and Regeneron's (NASDAQ: REGN ) blockbuster wet-age related macular degeneration, or wet-AMD, drugs Lucentis and Eylea.

    Both Novartis and Regeneron are reaping multibillions of dollars in sales for their wet-AMD drugs, and given that aging baby boomers are likely to increase the prevalence of this age related disease in the coming decade, new therapies like Ophthotech's Fovista could similarly put up blockbuster sales numbers one day.

    Fovista is currently in phase 3 trials, so the drug isn't up for consideration by the FDA yet. But results from previous trials have been compelling. In one mid-stage study, using Fovista alongside Novartis' Lucentis improved vision by 10.6 letters on a standard eye chart versus 6.5 letters for patients receiving Lucentis alone. Those results were good enough for Novartis to agree to license rights to Fovista overseas.

    As part of that deal, Novartis has already paid Ophthotech $200 million, and Ophthotech could receive up to another $800 million in milestones if Fovista pans out. The fact that Ophthotech has a been-there-done-that partner with deep pockets, and in a proven indication, is particularly intriguing when we consider that Ophthotech's market cap is less than $2 billion.

    : )

  • beareclawe beareclawe Mar 29, 2015 9:09 AM Flag

    Re: ... come on man, come up with something better than the disclaimers.......I mean this is actc/ocat.......there is plenty to work ...

    Citations:

    "Relax ..."

    dyooperya • Jan 12, 2015 7:31 PM
    Everybody.......................
    Relax......(as the greatest Quarter Back in the NFL likes to say)........This company didn't clean their books, pay off AG, hire a CEO and RS because they are going BK.........Something is cooking, it's just that nobody but PW and friends know just what is in the pot........In fact I'll bet a six pack of Cheese Head beer, that this little pos, past pink sheet stock is about to announce some ex-cell-ent news.......now watch an LeaRnT$$$$$............Say, has anyone seen Parsons around.....??

    "dEW yer oWn Dd......!!!!!$$$$$$"

    dyooperya • Feb 16, 2015 6:53 PM
    Heffernan nOSe sumTing IHMO.....!!!!$$$$$$
    dEW yer oWn Dd......!!!!!$$$$$$

    "wATch aN LeaRnT"

    dyooperya • Feb 25, 2015 6:45 AM
    aCTcOCaT = sTocK oF CenTURy......!!!!$$$$$$$ wATch aN LeaRnT

    : )

ACTC
6.97+0.17(+2.50%)Nov 13 3:59 PMEST